

Supporting Information

Selective synthesis of β -nitrated N-heterocycles and N-nitroso-2-alkoxyamine aldehydes from inactivated cyclic amines promoted by t BuONO and oxoammonium salt

Yan He,* Zhi Zheng, Yajie Liu, Jiajie Qiao, Xinying Zhang, and Xuesen Fan*

Henan Key Laboratory of Organic Functional Molecules and Drug Innovation, Key Laboratory for Yellow River and Huai River Water Environmental Pollution Control, Ministry of Education, Collaborative Innovation Center of Henan Province for Green Manufacturing of Fine Chemicals, School of Environment, School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, Henan 453007, China

E-mail: heyang@htu.cn; xuesen.fan@htu.cn

Contents

I	General experimental information	2
II	Experimental procedures and spectroscopic data	3-31
III	Copies of the NMR spectra of 2a-2p , 2' , 2'' , I , II , and III	32-72
IV	Copies of the NMR spectra of 3a-3t	73-97
V	Copies of the NMR spectra of 4a-4d	98-102
VI	Copies of the NMR spectra of 5a-5d	103-108
VII	X-ray crystal structure and data of 2m	109-110
VIII	Copies of DEPT 135, 90, C-H HSQC and H-H COSY spectra of 3a	111-112
IX	Copies of DEPT 135, 90, C-H HSQC, H-H COSY, C-H HMBC and H-H TOCSY spectra of 4d and 5c	113-120
X	References	121

I. General experimental information

Acetone was used without further purification, and the other solvents were dried before using. *Tert*-Butyl nitrite and $\text{BF}_3 \cdot \text{Et}_2\text{O}$ were purchased from commercial source and dried before using. T^+BF_4^- was synthesized with a previously described procedure.¹ *N*-Aryl cyclic amines (**1**) were prepared based on a literature procedure.² Melting points were recorded with a micro melting point apparatus and uncorrected. The ^1H NMR spectra were recorded at 400 MHz or 600 MHz, and the ^{13}C NMR spectra were recorded at 100 MHz or 150 MHz. The ^{19}F NMR spectra were recorded at 376 MHz or 565 MHz. Chemical shifts were expressed in parts per million (δ), and were reported as s (singlet), d (doublet), t (triplet), q (quadruplet), dd (doublet of doublet), td (doublet of triplet), m (multiplet), br s (broad singlet), etc. The coupling constants J were given in Hz. High-resolution mass spectra (HRMS) were performed on a microTOF mass spectrometer. All the reactions were monitored by thin-layer chromatography (TLC) using silica gel plates (silica gel 60 F254 0.25 mm), and components were visualized by observation under UV light (254 and 365 nm).

II. Experimental procedures and spectroscopic data

1. Optimization of reaction conditions

Table S1. Optimization studies on the formation of **2a** and **3a**^a

Entry	Oxidant (equiv.)	Additive (equiv.)	Solvent	Yield (%) ^b	
				2a	3a
1	T ⁺ BF ₄ ⁻ (1)	-	THF	11	-
2	T ⁺ ClO ₄ ⁻ (1)	-	THF	9	-
3	T ⁺ PF ₆ ⁻ (1)	-	THF	9	-
4	TEMPO (1)	-	THF	trace	-
5	T ⁺ BF ₄ ⁻ (0.5)	-	THF	trace	-
6	T ⁺ BF ₄ ⁻ (2)	-	THF	11	-
7 ^c	T ⁺ BF ₄ ⁻ (1)	4 Å MS	THF	40	-
8	T ⁺ BF ₄ ⁻ (1)	B(C ₆ F ₅) ₃ (1)	THF	9 (21) ^d	-
9	T ⁺ BF ₄ ⁻ (1)	BF ₃ ·Et ₂ O (1)	THF	24 (11) ^d	-
10	T ⁺ BF ₄ ⁻ (1)	<i>p</i> -NBA (1)	THF	trace	-
11	T ⁺ BF ₄ ⁻ (1)	NaHCO ₃ (1)	THF	11	-
12 ^c	T ⁺ BF ₄ ⁻ (1)	4 Å MS + B(C ₆ F ₅) ₃ (1)	THF	30 (52) ^d	-
13 ^c	T⁺BF₄⁻ (1)	4 Å MS + BF₃·Et₂O (1)	THF	61 (46)^d	-
14 ^{c,e}	T ⁺ BF ₄ ⁻ (1)	4 Å MS + BF ₃ ·Et ₂ O (1)	THF	57	-
15	T ⁺ BF ₄ ⁻ (1)	-	acetone/H ₂ O = 1/9	-	15
16	T ⁺ BF ₄ ⁻ (1)	-	acetone/H ₂ O = 1/4	-	30
17	T ⁺ BF ₄ ⁻ (1)	-	acetone/H ₂ O = 1/1	-	42
18	T ⁺ BF ₄ ⁻ (1)	-	acetone/H ₂ O = 4/1	-	36
19	T ⁺ BF ₄ ⁻ (1)	-	H ₂ O	-	28
20	T ⁺ BF ₄ ⁻ (2)	-	acetone/H ₂ O = 1/1	-	56
21	T ⁺ BF ₄ ⁻ (3)	-	acetone/H ₂ O = 1/1	-	52
22 ^f	T⁺BF₄⁻ (2)	-	acetone/H₂O = 1/1	-	68

^a Conditions: **1a** (0.2 mmol), TBN (0.6 mmol), solvent (1 mL), room temperature, air, 1 h. ^b Isolated yields. ^c 4 Å MS (100 mg). ^d B(C₆F₅)₃/BF₃·Et₂O (0.02 mmol). ^e Under O₂ (1 atm). ^f TBN (0.3 mmol).

Based on our previous studies, we commenced this work by treating 1-phenylpiperidine (**1a**) with TBN (3 equiv.) and T⁺BF₄⁻ (1 equiv.) in THF at rt under air for 1 h, from which 5-nitro-1-phenyl-1,2,3,4-tetrahydropyridine (**2a**) was obtained in a yield of 11% (Table S1, entry 1). In order to improve the efficiency of this reaction, different TEMPO salts and 2,2,6,6-tetramethyl-piperidinooxy (TEMPO) were tried, and T⁺BF₄⁻ was found to be more effective than T⁺ClO₄⁻, T⁺PF₆⁻, and TEMPO (entry 1 vs entries 2-4). Changing the amount of T⁺BF₄⁻ could not improve the yield of **2a** (entries 5-6). To see whether the presence of an additive could improve

this reaction, 4 Å molecular sieves (4 Å MS), B(C₆F₅)₃, BF₃ Et₂O, *p*-NBA (4-nitrobenzoic acid) and NaHCO₃ were tried (entries 7-11). Delightfully, by using 4 Å MS, B(C₆F₅)₃ (0.1 equiv.) or BF₃ Et₂O (1 equiv.) as an additive, the yield of **2a** was improved to 40%, 21% or 24%, respectively (entries 7-9). When a combination of 4 Å MS and B(C₆F₅)₃ (0.1 equiv.)/BF₃ Et₂O (1 equiv.) was used as the additive, **2a** was obtained in higher yields of 52% and 61%, respectively (entries 12-13). It is noted herein that the formation of acyclic by-products such as *N*-(4-(hydroxyimino)-5-oxopentyl)-*N*-phenylnitrous amide (**2a'**, 17%) and *N*-(3-cyanopropyl)-*N*-phenylformamide (**2a''**, 8%) was also detected (entry 13). Then, the reaction was run under O₂ instead of air, from which a slightly lower yield of **2a** was observed (entry 14). In another respect, when a mixture of acetone and water (v/v, 1/9) was used as the reaction medium, *N*-(5-oxo-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)pent-yl)-*N*-phenylnitrous amide (**3a**) instead of **2a** was obtained in a yield of 15% (entry 15 vs entry 1). Following optimization with regard to different ratios of acetone with water as solvent revealed that 1/1 is the most suitable for this transformation (entry 17 vs entries 15-19). Considering T⁺BF₄⁻ might be used as both oxidant and substrate, the loading of T⁺BF₄⁻ was increased from 1 equiv. to 2 equiv. and 3 equiv. (entries 20-21). It turned out that using 2 equiv. of T⁺BF₄⁻ could guarantee a higher yield of **3a** (entry 20). It was also found that using 1.5 equiv. of TBN generated the optimum result (entry 22).

With entry 1 in Table S2 as model reaction conditions for the formation of **2a**, solvent effect was investigated. In dioxane or acetone lower reactivity was observed, 52% and 46% of **2a** were formed, respectively (entries 2-3). Further experiment demonstrated that also DMF is less effective solvent to lead to the formation of **2a** (31%) and **3a** (11%) (entry 4). Then, it was found that when CH₃CN was used, the reaction efficiency was dramatically reduced to afford **2a** in 9% yield (entry 5). In addition, when DMSO and chlorinated solvents such as DCM and DCE were used as the reaction medium in the reaction, turned out to be messy to give an unknown mixture, from which the desired product was not obtained (entries 6-8). On the other hand, with entry 9 as model reaction conditions for the formation of **3a**, the mixtures of different organic solvents and water (1/1) as the reaction medium were also investigated. These mixtures showed similar reactivity (entries 9-14). Among them, the mixture of acetone and water was the most effective solvent to give **3a** in a highest yield of 68% (entry 9).

Table S2. Optimization studies on the solvents for the formation of **2a** and **3a**^a

c1ccc(cc1)N2CCCCC2 + CC(C)(C)O=NO $\xrightarrow{\text{conditions}}$ c1ccc(cc1)N2C=CC(=C(C=C2)[N+](=O)[O-]) + c1ccc(cc1)N2C=CC(=C(C=C2)[N+](=O)[O-])C3CCCCC3

1a
2a
3a

Entry	Oxidant (equiv.)	Additive (equiv.)	Solvent	Yield (%) ^b	
				2a	3a
1^c	T⁺BF₄⁻ (1)	4 Å MS + BF₃·Et₂O (1)	THF	61	-
2 ^c	T ⁺ BF ₄ ⁻ (1)	4 Å MS + BF ₃ ·Et ₂ O (1)	dioxane	52	-
3 ^c	T ⁺ BF ₄ ⁻ (1)	4 Å MS + BF ₃ ·Et ₂ O (1)	acetone	46	-
4 ^c	T ⁺ BF ₄ ⁻ (1)	4 Å MS + BF ₃ ·Et ₂ O (1)	DMF	31	11
5 ^c	T ⁺ BF ₄ ⁻ (1)	4 Å MS + BF ₃ ·Et ₂ O (1)	CH ₃ CN	9	-
6 ^c	T ⁺ BF ₄ ⁻ (1)	4 Å MS + BF ₃ ·Et ₂ O (1)	DMSO	-	-
7 ^c	T ⁺ BF ₄ ⁻ (1)	4 Å MS + BF ₃ ·Et ₂ O (1)	DCM	-	-
8 ^c	T ⁺ BF ₄ ⁻ (1)	4 Å MS + BF ₃ ·Et ₂ O (1)	DCE	-	-
9^d	T⁺BF₄⁻ (2)	-	acetone/H₂O = 1/1	-	68
10 ^d	T ⁺ BF ₄ ⁻ (2)	-	dioxane/H ₂ O = 1/1	-	64
11 ^d	T ⁺ BF ₄ ⁻ (2)	-	DMF/H ₂ O = 1/1	-	56
12 ^d	T ⁺ BF ₄ ⁻ (2)	-	DMSO/H ₂ O = 1/1	-	51
13 ^d	T ⁺ BF ₄ ⁻ (2)	-	CH ₃ CN/H ₂ O = 1/1	-	50
14 ^d	T ⁺ BF ₄ ⁻ (2)	-	THF/H ₂ O = 1/1	-	61

^a Conditions: **1a** (0.2 mmol), TBN (0.6 mmol), solvent (1 mL), room temperature, air, 1 h. ^b Isolated yields. ^c 4 Å MS (100 mg). ^d TBN (0.3 mmol).

2. A typical procedure for the synthesis of **2a** the spectroscopic data of **2a-2n**, **2'**, and **2''**

To a reaction tube equipped with a stir bar were added 1-phenylpiperidine (**1a**, 32 mg, 0.2 mmol), THF (1 mL), T⁺BF₄⁻ (49 mg, 0.2 mmol), *tert*-butyl nitrite (98%, 73 μL, 0.6 mmol), 4 Å molecular sieves (100 mg, activated at 500 °C for 5 h before use), and BF₃·Et₂O (98%, 25 μL). The resulting mixture was then stirred at room temperature under air for 1 h. Upon completion, the reaction was diluted with ethyl acetate and washed with aqueous NaCl and saturated NaHCO₃ solution. The organic layer was dried over anhydrous Na₂SO₄ and filtered. Then, the solvent was evaporated under vacuum and the crude product was purified by column chromatography on silica-gel with petroleum ether/ethyl acetate (5:1) as the eluent to afford **2a** as yellow solid in 25 mg (61%). By-products **2a'** and **2a''** were also obtained as yellow/red liquid in (8 mg) 17% and (3 mg) 8%, respectively. **2b-2n**, **2'**, and **2''** were obtained in an analogous manner.

1 mmol scale procedure for the synthesis of 2a

To a reaction tube equipped with a stir bar were added 1-phenylpiperidine (**1a**, 161 mg, 1 mmol), THF (5 mL), T⁺BF₄⁻ (243 mg, 1 mmol), *tert*-butyl nitrite (98%, 364 μL, 3 mmol), 4 Å molecular sieves (500 mg, activated at 500 °C for 5 h before use), and BF₃·Et₂O (98%, 126 μL). The resulting mixture was then stirred at room temperature under air for 1 h. Upon completion, the reaction was diluted with ethyl acetate and washed with aqueous NaCl and saturated NaHCO₃ solution. The organic layer was dried over anhydrous Na₂SO₄ and filtered. Then, the solvent was evaporated under vacuum and the crude product was purified by column chromatography on silica-gel with petroleum ether/ethyl acetate (5:1) as the eluent to afford **2a** as yellow solid in 110 mg (54%).

5-Nitro-1-phenyl-1,2,3,4-tetrahydropyridine (2a)

Eluent: petroleum ether/ethyl acetate (5:1), Yellow solid (25 mg, 61%), m.p.: 81-82 °C. ¹H NMR (400 MHz, CDCl₃) δ: 2.08-2.12 (m, 2H), 2.80 (t, *J* = 6.4 Hz, 2H), 3.70 (t, *J* = 6.4 Hz, 2H), 7.16-7.23 (m, 3H), 7.41 (t, *J* = 7.6 Hz, 2H), 8.57 (s, 1H). ¹³C NMR (150 MHz, CDCl₃) δ: 20.5, 21.2, 46.9, 119.1, 125.3, 125.4, 129.8, 141.0, 144.6. HRMS calcd for C₁₁H₁₃N₂O₂: 205.0972 [M+H]⁺, found: 205.0968.

N-(4-(Hydroxyimino)-5-oxopentyl)-*N*-phenylnitrous amide (2a')³

Eluent: petroleum ether/ethyl acetate (5:1), red liquid (8 mg, 17%). ¹H NMR (400 MHz, CDCl₃) δ: 1.74-1.78 (m, 2H), 2.51 (t, *J* = 7.6 Hz, 2H), 4.04 (t, *J* = 7.6 Hz, 2H), 7.36-7.40 (m, 1H), 7.46-7.53 (m, 4H), 9.45 (br s, 2H). ¹³C NMR (150 MHz, CDCl₃) δ: 18.3, 21.3, 42.8, 119.0, 126.6, 128.6, 140.3, 158.8, 189.7.

N-(3-Cyanopropyl)-*N*-phenylformamide (2a'')⁴

Eluent: petroleum ether/ethyl acetate (2:1), Yellow liquid (3 mg, 8%). ¹H NMR (400 MHz, CDCl₃) δ: 1.93-1.97 (m, 2H), 2.38 (t, *J* = 7.2 Hz, 2H), 3.95 (t, *J* = 7.2 Hz, 2H), 7.19 (d, *J* = 7.6 Hz, 2H),

7.34 (t, $J = 7.2$ Hz, 1H), 7.45 (t, $J = 7.6$ Hz, 2H), 8.40 (s, 1H).

1-(4-Fluorophenyl)-5-nitro-1,2,3,4-tetrahydropyridine (2b)

Eluent: petroleum ether/ethyl acetate (5:1), Yellow solid (30 mg, 68%), m.p.: 93-94 °C. ^1H NMR (400 MHz, CDCl_3) δ : 2.08-2.10 (m, 2H), 2.79 (t, $J = 6.4$ Hz, 2H), 3.66 (t, $J = 6.0$ Hz, 2H), 7.11-7.14 (m, 4H), 8.48 (s, 1H). ^{13}C NMR (150 MHz, CDCl_3) δ : 20.5, 21.0, 47.4, 116.6 (d, $^2J_{\text{C-F}} = 23.1$ Hz), 121.0 (d, $^3J_{\text{C-F}} = 8.7$ Hz), 125.3, 141.0 (d, $^4J_{\text{C-F}} = 2.3$ Hz), 141.1, 160.2 (d, $^1J_{\text{C-F}} = 245.1$ Hz). ^{19}F NMR (565 MHz, CDCl_3) δ : -116.4. HRMS calcd for $\text{C}_{11}\text{H}_{12}\text{FN}_2\text{O}_2$: 223.0877 $[\text{M}+\text{H}]^+$, found: 223.0868.

***N*-(4-Fluorophenyl)-*N*-(4-(hydroxyimino)-5-oxopentyl)nitrous amide (2b')³**

Eluent: petroleum ether/ethyl acetate (5:1), red liquid (5 mg, 10%). ^1H NMR (400 MHz, CDCl_3) δ : 1.71-1.75 (m, 2H), 2.49 (t, $J = 7.6$ Hz, 2H), 4.00 (t, $J = 7.6$ Hz, 2H), 7.16-7.20 (m, 2H), 7.45-7.48 (m, 2H), 9.11 (br s, 1H), 9.44 (s, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ : 19.3, 22.3, 44.0, 116.5 (d, $^2J_{\text{C-F}} = 23.1$ Hz), 122.2 (d, $^3J_{\text{C-F}} = 7.9$ Hz), 137.5 (d, $^4J_{\text{C-F}} = 2.9$ Hz), 160.0, 161.9 (d, $^1J_{\text{C-F}} = 246.3$ Hz), 190.7. ^{19}F NMR (565 MHz, CDCl_3) δ : -113.9.

1-(4-Chlorophenyl)-5-nitro-1,2,3,4-tetrahydropyridine (2c)

Eluent: petroleum ether/ethyl acetate (5:1), Yellow solid (31 mg, 65%), m.p.: 100-101 °C. ^1H NMR (600 MHz, CDCl_3) δ : 2.09-2.10 (m, 2H), 2.79 (t, $J = 6.0$ Hz, 2H), 3.66 (t, $J = 5.4$ Hz, 2H), 7.10 (d, $J = 8.4$ Hz, 2H), 7.37 (d, $J = 8.4$ Hz, 2H), 8.50 (s, 1H). ^{13}C NMR (150 MHz, CDCl_3) δ : 20.4, 21.1, 46.9, 120.1, 126.0, 129.8, 130.7, 140.2, 143.2. HRMS calcd for $\text{C}_{11}\text{H}_{12}\text{ClN}_2\text{O}_2$: 239.0582 $[\text{M}+\text{H}]^+$, found: 239.0563.

***N*-(4-Chlorophenyl)-*N*-(4-(hydroxyimino)-5-oxopentyl)nitrous amide (2c')³**

Eluent: petroleum ether/ethyl acetate (5:1), red liquid (8 mg, 15%). ^1H NMR (400 MHz, CDCl_3) δ : 1.70-1.74 (m, 2H), 2.49 (t, $J = 7.6$ Hz, 2H), 4.00 (t, $J = 7.6$ Hz, 2H), 7.45 (br s, 4H), 9.45 (s, 1H).

^{13}C NMR (150 MHz, CDCl_3) δ : 19.3, 22.3, 43.4, 120.9, 129.8, 133.2, 139.9, 159.8, 190.6.

1-(4-Bromophenyl)-5-nitro-1,2,3,4-tetrahydropyridine (2d)

Eluent: petroleum ether/ethyl acetate (5:1), Yellow solid (40 mg, 71%), m.p.: 111-112 °C. ^1H NMR (600 MHz, CDCl_3) δ : 2.08-2.10 (m, 2H), 2.79 (t, $J = 6.0$ Hz, 2H), 3.65 (t, $J = 6.0$ Hz, 2H), 7.04 (dd, $J_1 = 6.6$ Hz, $J_2 = 1.8$ Hz, 2H), 7.52 (dd, $J_1 = 6.6$ Hz, $J_2 = 1.8$ Hz, 2H), 8.50 (s, 1H). ^{13}C NMR (150 MHz, CDCl_3) δ : 20.4, 21.1, 46.8, 118.3, 120.4, 126.1, 132.8, 140.0, 143.6. HRMS calcd for $\text{C}_{11}\text{H}_{12}\text{BrN}_2\text{O}_2$: 283.0077 $[\text{M}+\text{H}]^+$, found: 283.0074.

***N*-(4-Bromophenyl)-*N*-(4-(hydroxyimino)-5-oxopentyl)nitrous amide (2d')³**

Eluent: petroleum ether/ethyl acetate (5:1), red liquid (7 mg, 11%). ^1H NMR (400 MHz, CDCl_3) δ : 1.68-1.76 (m, 2H), 2.49 (t, $J = 7.6$ Hz, 2H), 3.99 (t, $J = 7.6$ Hz, 2H), 7.40 (dd, $J_1 = 6.8$ Hz, $J_2 = 2.0$ Hz, 2H), 7.60 (dd, $J_1 = 6.8$ Hz, $J_2 = 2.0$ Hz, 2H), 8.93, (br s, 1H), 9.45 (s, 1H). ^{13}C NMR (150 MHz, CDCl_3) δ : 19.3, 22.3, 43.3, 121.0, 121.1, 132.7, 140.4, 159.8, 190.6.

4-(5-Nitro-3,4-dihydropyridin-1(2H)-yl)benzotrile (2e)

Eluent: petroleum ether/ethyl acetate (5:1), Yellow syrup (27 mg, 59%). ^1H NMR (600 MHz, CDCl_3) δ : 2.13-2.15 (m, 2H), 2.81 (t, $J = 6.0$ Hz, 2H), 3.70 (t, $J = 6.0$ Hz, 2H), 7.24 (dd, $J_1 = 6.6$ Hz, $J_2 = 1.8$ Hz, 2H), 7.70 (dd, $J_1 = 6.6$ Hz, $J_2 = 1.8$ Hz, 2H), 8.54 (s, 1H). ^{13}C NMR (150 MHz, CDCl_3) δ : 20.4, 21.1, 46.2, 107.6, 118.2, 118.3, 128.3, 133.9, 138.1, 147.5. HRMS calcd for $\text{C}_{12}\text{H}_{12}\text{N}_3\text{O}_2$: 230.0924 $[\text{M}+\text{H}]^+$, found: 230.0903.

***N*-(4-Cyanophenyl)-*N*-(4-(hydroxyimino)-5-oxopentyl)nitrous amide (2e')**

Eluent: petroleum ether/ethyl acetate (5:1), red liquid (7 mg, 13%). ^1H NMR (400 MHz, CDCl_3) δ : 1.69-1.75 (m, 2H), 2.51 (t, $J = 7.6$ Hz, 2H), 4.01 (t, $J = 7.6$ Hz, 2H), 7.67-7.69 (m, 2H), 7.78 (dd, $J_1 = 6.8$ Hz, $J_2 = 2.0$ Hz, 2H), 8.67, (br s, 1H), 9.46 (s, 1H). ^{13}C NMR (150 MHz, CDCl_3) δ : 19.2, 22.2, 42.3, 110.4, 118.2, 118.5, 133.8, 144.7, 159.6, 190.6. HRMS calcd for $\text{C}_{12}\text{H}_{12}\text{N}_4\text{O}_3\text{Na}$: 283.0802

[M+Na]⁺, found: 283.0824.

5-Nitro-1-(*p*-tolyl)-1,2,3,4-tetrahydropyridine (2f)

Eluent: petroleum ether/ethyl acetate (5:1), Yellow solid (11 mg, 25%), m.p.: 109-110 °C. ¹H NMR (600 MHz, CDCl₃) δ: 2.07-2.09 (m, 2H), 2.35 (s, 3H), 2.79 (t, *J* = 6.0 Hz, 2H), 3.67 (t, *J* = 6.0 Hz, 2H), 7.06 (d, *J* = 8.4 Hz, 2H), 7.20 (d, *J* = 7.8 Hz, 2H), 8.55 (s, 1H). ¹³C NMR (150 MHz, CDCl₃) δ: 20.5, 20.8, 21.2, 47.2, 119.2, 124.7, 130.3, 135.4, 141.3, 142.3. HRMS calcd for C₁₂H₁₅N₂O₂: 219.1128 [M+H]⁺, found: 219.1123.

***N*-(4-(Hydroxyimino)-5-oxopentyl)-*N*-(*p*-tolyl)nitrous amide (2f')³**

Eluent: petroleum ether/ethyl acetate (5:1), red liquid (18 mg, 36%). ¹H NMR (600 MHz, CDCl₃) δ: 1.72-1.77 (m, 2H), 2.39 (s, 3H), 2.50 (t, *J* = 7.8 Hz, 2H), 4.02 (t, *J* = 7.2 Hz, 2H), 7.26 (d, *J* = 8.4 Hz, 2H), 7.37 (d, *J* = 8.4 Hz, 2H), 9.44 (s, 1H), 10.01 (br s, 1H). ¹³C NMR (150 MHz, CDCl₃) δ: 19.3, 21.0, 22.3, 44.2, 120.3, 130.2, 137.9, 138.8, 159.8, 191.0.

1-(3-Fluorophenyl)-5-nitro-1,2,3,4-tetrahydropyridine (2g)

Eluent: petroleum ether/ethyl acetate (5:1), Yellow liquid (27 mg, 61%). ¹H NMR (600 MHz, CDCl₃) δ: 2.09-2.11 (m, 2H), 2.79 (t, *J* = 6.6 Hz, 2H), 3.67 (t, *J* = 5.4 Hz, 2H), 6.87-6.90 (m, 2H), 6.96 (dd, *J*₁ = 8.4 Hz, *J*₂ = 1.8 Hz, 1H), 7.37 (dd, *J*₁ = 8.4 Hz, *J*₂ = 1.8 Hz, 1H), 8.52 (s, 1H). ¹³C NMR (150 MHz, CDCl₃) δ: 20.4, 21.1, 46.7, 106.2 (d, ²*J*_{C-F} = 25.2 Hz), 111.9 (d, ²*J*_{C-F} = 20.9 Hz), 114.2 (d, ⁴*J*_{C-F} = 3.3 Hz), 126.3, 131.1 (d, ³*J*_{C-F} = 8.7 Hz), 139.9, 146.0 (d, ³*J*_{C-F} = 8.7 Hz), 163.4 (d, ¹*J*_{C-F} = 247.2 Hz). ¹⁹F NMR (565 MHz, CDCl₃) δ: -110.0. HRMS calcd for C₁₁H₁₂FN₂O₂: 223.0877 [M+H]⁺, found: 223.0870.

***N*-(3-Cyanopropyl)-*N*-(3-fluorophenyl)formamide (2g'')⁴**

Eluent: petroleum ether/ethyl acetate (2:1), Yellow liquid (7 mg, 17%). ¹H NMR (400 MHz, CDCl₃) δ: 1.94-1.97 (m, 2H), 2.40 (t, *J* = 7.2 Hz, 2H), 3.95 (t, *J* = 6.8 Hz, 2H), 6.92-7.07 (m, 3H), 7.41-7.43

(m, 1H), 8.44 (s, 1H).

1-(3-Chlorophenyl)-5-nitro-1,2,3,4-tetrahydropyridine (2h)

Eluent: petroleum ether/ethyl acetate (5:1), Yellow solid (29 mg, 61%), m.p.: 100-101 °C. ¹H NMR (600 MHz, CDCl₃) δ: 2.09-2.11 (m, 2H), 2.79 (t, *J* = 6.6 Hz, 2H), 3.66 (t, *J* = 6.0 Hz, 2H), 7.05-7.07 (m, 1H), 7.16-7.18 (m, 2H), 7.33 (t, *J* = 7.8 Hz, 1H), 8.51 (s, 1H). ¹³C NMR (150 MHz, CDCl₃) δ: 20.4, 21.1, 46.7, 116.8, 119.1, 125.1, 126.4, 130.8, 135.6, 139.9, 145.6. HRMS calcd for C₁₁H₁₂ClN₂O₂: 239.0582 [M+H]⁺, found: 239.0577.

***N*-(3-Chlorophenyl)-*N*-(3-cyanopropyl)formamide (2h'')⁴**

Eluent: petroleum ether/ethyl acetate (2:1), Yellow liquid (7 mg, 16%). ¹H NMR (400 MHz, CDCl₃) δ: 1.93-1.97 (m, 2H), 2.40 (t, *J* = 7.6 Hz, 2H), 3.94 (t, *J* = 7.2 Hz, 2H), 7.10 (d, *J* = 7.6 Hz, 1H), 7.21 (d, *J* = 1.2 Hz, 1H), 7.32-7.39 (m, 2H), 8.41 (s, 1H).

1-(3-Bromophenyl)-5-nitro-1,2,3,4-tetrahydropyridine (2i)

Eluent: petroleum ether/ethyl acetate (5:1), Yellow solid (36 mg, 64%), m.p.: 123-124 °C. ¹H NMR (600 MHz, CDCl₃) δ: 2.08-2.10 (m, 2H), 2.79 (t, *J* = 6.6 Hz, 2H), 3.66 (t, *J* = 6.0 Hz, 2H), 7.09-7.11 (m, 1H), 7.26-7.28 (m, 1H), 7.32-7.33 (m, 2H), 8.50 (s, 1H). ¹³C NMR (150 MHz, CDCl₃) δ: 20.4, 21.1, 46.8, 117.3, 122.0, 123.5, 126.4, 128.1, 131.0, 139.8, 145.7. HRMS calcd for C₁₁H₁₂BrN₂O₂: 283.0077 [M+H]⁺, found: 283.0054.

***N*-(3-Bromophenyl)-*N*-(3-cyanopropyl)formamide (2i'')⁴**

Eluent: petroleum ether/ethyl acetate (2:1), Yellow liquid (11 mg, 21%). ¹H NMR (400 MHz, CDCl₃) δ: 1.91-1.98 (m, 2H), 2.40 (t, *J* = 7.2 Hz, 2H), 3.94 (t, *J* = 6.8 Hz, 2H), 7.15 (d, *J* = 7.6 Hz, 1H), 7.31-7.36 (m, 2H), 7.48 (d, *J* = 8.0 Hz, 1H), 8.40 (s, 1H).

1-(2-Chlorophenyl)-5-nitro-1,2,3,4-tetrahydropyridine (2j)

Eluent: petroleum ether/ethyl acetate (5:1), Yellow solid (20 mg, 42%), m.p.: 90-91 °C. ¹H NMR

(600 MHz, CDCl₃) δ : 2.08-2.12 (m, 2H), 2.81 (t, J = 6.0 Hz, 2H), 3.58 (t, J = 6.0 Hz, 2H), 7.24-7.25 (m, 1H), 7.30 (td, J_1 = 7.2 Hz, J_2 = 1.8 Hz, 1H), 7.34 (dd, J_1 = 7.8 Hz, J_2 = 1.8 Hz, 1H), 7.48 (dd, J_1 = 7.8 Hz, J_2 = 1.2 Hz, 1H), 8.23 (s, 1H). ¹³C NMR (150 MHz, CDCl₃) δ : 20.5, 21.1, 49.1, 124.2, 127.5, 128.3, 129.0, 130.4, 131.1, 142.5, 144.0. HRMS calcd for C₁₁H₁₂ClN₂O₂: 239.0582 [M+H]⁺, found: 239.0578.

1-(Naphthalen-1-yl)-5-nitro-1,2,3,4-tetrahydropyridine (2k)

Eluent: petroleum ether/ethyl acetate (5:1), Yellow solid (26 mg, 51%), m.p.: 112-113 °C. ¹H NMR (600 MHz, CDCl₃) δ : 2.19-2.23 (m, 2H), 2.91 (br s, 2H), 3.70 (br s, 2H), 7.34-7.35 (m, 1H), 7.48-7.51 (m, 1H), 7.56-7.61 (m, 2H), 7.80 (d, J = 7.8 Hz, 1H), 7.87 (d, J = 7.8 Hz, 1H), 7.93-7.95 (m, 1H), 8.39 (s, 1H). ¹³C NMR (150 MHz, CDCl₃) δ : 20.9, 21.3, 50.2, 122.1, 123.2, 123.5, 125.6, 127.0, 127.5, 128.6, 128.8, 128.9, 134.7, 141.9, 145.2. HRMS calcd for C₁₅H₁₅N₂O₂: 255.1128 [M+H]⁺, found: 255.1123.

***N*-(3-Cyanopropyl)-*N*-(naphthalen-1-yl)formamide (2k'')⁴**

Eluent: petroleum ether/ethyl acetate (2:1), Yellow liquid (7 mg, 15%). ¹H NMR (400 MHz, CDCl₃) δ : 1.97-1.98 (m, 2H), 2.41-2.43 (m, 2H), 3.64-3.65 (m, 1H), 4.28 (br s, 1H), 7.36 (d, J = 7.2 Hz, 1H), 7.53 (t, J = 7.6 Hz, 1H), 7.57-7.63 (m, 2H), 7.78 (d, J = 8.0 Hz, 1H), 7.93-7.97 (m, 2H), 8.29 (s, 1H).

4-Methyl-5-nitro-1-phenyl-1,2,3,4-tetrahydropyridine (2l)

Eluent: petroleum ether/ethyl acetate (5:1), Yellow liquid (26 mg, 60%). ¹H NMR (600 MHz, CDCl₃) δ : 1.26 (d, J = 6.6 Hz, 3H), 1.89-1.92 (m, 1H), 2.00-2.03 (m, 1H), 3.31-3.33 (m, 1H), 3.69-3.72 (m, 2H), 7.19-7.23 (m, 3H), 7.40-7.43 (m, 2H), 8.57 (s, 1H). ¹³C NMR (150 MHz, CDCl₃) δ : 19.7, 25.4, 27.4, 43.0, 119.0, 125.4, 129.8, 129.9, 140.4, 144.5. HRMS calcd for C₁₂H₁₅N₂O₂: 219.1128 [M+H]⁺, found: 219.1104.

***N*-(4-(Hydroxyimino)-3-methyl-5-oxopentyl)-*N*-phenylnitrous amide (2l')**

Eluent: petroleum ether/ethyl acetate (5:1), Red liquid (10 mg, 20%). ¹H NMR (600 MHz, CDCl₃) δ: 1.20 (d, *J* = 7.2 Hz, 3H), 1.82-1.85 (m, 1H), 2.11-2.14 (m, 1H), 3.23-3.25 (m, 1H), 3.78-3.83 (m, 1H), 4.07-4.11 (m, 1H), 7.35-7.38 (m, 1H), 7.45-7.50 (m, 4H), 9.40 (br s, 2H). ¹³C NMR (150 MHz, CDCl₃) δ: 16.2, 27.4, 29.0, 42.4, 119.9, 127.7, 129.6, 141.2, 162.1, 191.2. HRMS calcd for C₁₂H₁₅N₃O₃Na: 272.1006 [M+Na]⁺, found: 272.1020.

***N*-(3-Cyanobutyl)-*N*-phenylformamide (2l'')⁴**

Eluent: petroleum ether/ethyl acetate (2:1), Yellow liquid (3 mg, 7%). ¹H NMR (400 MHz, CDCl₃) δ: 1.35 (d, *J* = 7.2 Hz, 3H), 1.84-1.90 (m, 2H), 2.62-2.67 (m, 1H), 3.98 (t, *J* = 7.2 Hz, 2H), 7.19 (d, *J* = 8.0 Hz, 2H), 7.34 (t, *J* = 7.2 Hz, 1H), 7.45 (t, *J* = 7.6 Hz, 2H), 8.40 (s, 1H).

1-(4-Fluorophenyl)-4-methyl-5-nitro-1,2,3,4-tetrahydropyridine (2m)

Eluent: petroleum ether/ethyl acetate (5:1), Yellow solid (30 mg, 64%), m.p.: 96-97 °C. ¹H NMR (400 MHz, CDCl₃) δ: 1.25 (d, *J* = 6.8 Hz, 3H), 1.88-1.93 (m, 1H), 1.98-2.04 (m, 1H), 3.29-3.33 (m, 1H), 3.66-3.69 (m, 2H), 7.09-7.19 (m, 4H), 8.47 (s, 1H). ¹³C NMR (150 MHz, CDCl₃) δ: 19.7, 25.3, 27.4, 43.5, 116.6 (d, ²*J*_{C-F} = 23.0 Hz), 121.0 (d, ³*J*_{C-F} = 7.7 Hz), 129.8, 140.5, 141.0 (d, ⁴*J*_{C-F} = 3.3 Hz), 160.2 (d, ¹*J*_{C-F} = 245.1 Hz). ¹⁹F NMR (565 MHz, CDCl₃) δ: -116.4. HRMS calcd for C₁₂H₁₄FN₂O₂: 237.1034 [M+H]⁺, found: 237.1035.

***N*-(4-Fluorophenyl)-*N*-(4-(hydroxyimino)-3-methyl-5-oxopentyl)nitrous amide (2m')**

Eluent: petroleum ether/ethyl acetate (5:1), Red liquid (8 mg, 15%). ¹H NMR (600 MHz, CDCl₃) δ: 1.20 (d, *J* = 6.6 Hz, 3H), 1.80-1.85 (m, 1H), 2.09-2.13 (m, 1H), 3.21-3.25 (m, 1H), 3.75-3.80 (m, 1H), 4.05-4.10 (m, 1H), 7.16-7.18 (m, 2H), 7.45-7.47 (m, 2H), 9.40 (s, 1H), 9.55 (br s, 1H). ¹³C NMR (150 MHz, CDCl₃) δ: 16.1, 27.3, 28.9, 42.7, 116.5 (d, ²*J*_{C-F} = 23.0 Hz), 122.0 (d, ³*J*_{C-F} = 7.7 Hz), 137.4 (d, ⁴*J*_{C-F} = 3.3 Hz), 161.8, 161.9 (d, ¹*J*_{C-F} = 246.2 Hz), 191.1. ¹⁹F NMR (565 MHz,

CDCl₃) δ : -113.7. HRMS calcd for C₁₂H₁₄FN₃O₃Na: 290.0911 [M+Na]⁺, found: 290.0895.

1-(3-Chlorophenyl)-4-methyl-5-nitro-1,2,3,4-tetrahydropyridine (2n)

Eluent: petroleum ether/ethyl acetate (5:1), Yellow liquid (31 mg, 62%). ¹H NMR (400 MHz, CDCl₃) δ : 1.25 (d, *J* = 6.8 Hz, 3H), 1.89-1.93 (m, 1H), 1.99-2.02 (m, 1H), 3.29-3.32 (m, 1H), 3.65-3.69 (m, 2H), 7.07-7.10 (m, 1H), 7.16-7.19 (m, 2H), 7.32-7.36 (m, 1H), 8.51 (s, 1H). ¹³C NMR (150 MHz, CDCl₃) δ : 19.7, 25.4, 27.4, 42.9, 116.8, 119.1, 125.1, 130.8, 130.9, 135.6, 139.3, 145.5. HRMS calcd for C₁₂H₁₄ClN₂O₂: 253.0738 [M+H]⁺, found: 253.0739.

***N*-(3-Chlorophenyl)-*N*-(4-(hydroxyimino)-3-methyl-5-oxopentyl)nitrous amide (2n')**

Eluent: petroleum ether/ethyl acetate (5:1), Red liquid (6 mg, 11%). ¹H NMR (600 MHz, CDCl₃) δ : 1.21 (d, *J* = 7.2 Hz, 3H), 1.77-1.83 (m, 1H), 2.09-2.12 (m, 1H), 3.21-3.25 (m, 1H), 3.71-3.76 (m, 1H), 4.02-4.07 (m, 1H), 7.32-7.34 (m, 1H), 7.38-7.42 (m, 2H), 7.54 (s, 1H), 8.96 (br s, 1H), 9.40 (s, 1H). ¹³C NMR (150 MHz, CDCl₃) δ : 16.2, 27.4, 29.0, 41.9, 117.3, 119.6, 127.3, 130.6, 135.4, 142.4, 161.9, 191.0. HRMS calcd for C₁₂H₁₅ClN₃O₃: 284.0796 [M+H]⁺, found: 284.0794.

***N*-(3-Chlorophenyl)-*N*-(3-cyanobutyl)formamide (2n'')**⁴

Eluent: petroleum ether/ethyl acetate (2:1), Yellow liquid (3 mg, 6%). ¹H NMR (400 MHz, CDCl₃) δ : 1.36 (d, *J* = 6.8 Hz, 3H), 1.84-1.88 (m, 2H), 2.65-2.66 (m, 1H), 3.97 (t, *J* = 7.2 Hz, 2H), 7.10 (d, *J* = 7.6 Hz, 1H), 7.20 (s, 1H), 7.32 (d, *J* = 8.0 Hz, 1H), 7.39 (t, *J* = 8.0 Hz, 1H), 8.39 (s, 1H).

A typical procedure for the synthesis of 2o and the spectroscopic data of 2o and 2p

To a reaction tube equipped with a stir bar were added 1,4-diphenylpiperazine (**1o**, 48 mg, 0.2 mmol), THF (1 mL), T⁺BF₄⁻ (58 mg, 0.24 mmol), *tert*-butyl nitrite (98%, 73 μ L, 0.6 mmol), and 4 Å molecular sieves (100 mg, activated at 500 °C for 5 h before use). The resulting mixture was then stirred at room temperature under air for 1 h. Upon completion, the reaction was diluted with ethyl acetate and washed with aqueous NaCl and saturated NaHCO₃ solution. The organic layer was dried

over anhydrous Na₂SO₄ and filtered. Then, the solvent was evaporated under vacuum and the crude product was purified by column chromatography on silica-gel with petroleum ether/ethyl acetate (5:1) as the eluent to afford **2o** as yellow solid in 23 mg (41%). **2p** was obtained in an analogous manner.


5-Nitro-1,4-diphenyl-1,2,3,4-tetrahydropyrazine (2o)

Eluent: petroleum ether/ethyl acetate (5:1), Yellow solid (23 mg, 41%), m.p.: 154-155 °C. ¹H NMR (600 MHz, CDCl₃) δ: 3.59 (t, *J* = 4.8 Hz, 2H), 3.76 (t, *J* = 4.8 Hz, 2H), 7.00 (d, *J* = 7.8 Hz, 2H), 7.05 (t, *J* = 7.8 Hz, 1H), 7.19-7.21 (m, 3H), 7.32 (t, *J* = 7.8 Hz, 2H), 7.42 (t, *J* = 7.8 Hz, 2H), 8.62 (s, 1H). ¹³C NMR (150 MHz, CDCl₃) δ: 44.3, 48.8, 118.7, 120.4, 123.3, 125.2, 129.5, 129.88, 129.91, 130.0, 143.7, 147.1. HRMS calcd for C₁₆H₁₆N₃O₂: 282.1237 [M+H]⁺, found: 282.1233.

2-Nitro-1,4-diphenyl-4,5,6,7-tetrahydro-1*H*-1,4-diazepine (2p)

Eluent: petroleum ether/ethyl acetate (5:1), Yellow solid (18 mg, 31%), m.p.: 203-204 °C. ¹H NMR (600 MHz, CDCl₃) δ: 2.14-2.17 (m, 2H), 3.70-3.79 (m, 3H), 4.38-4.41 (m, 1H), 6.86 (d, *J* = 8.4 Hz, 2H), 6.91 (t, *J* = 7.2 Hz, 1H), 7.20-7.24 (m, 3H), 7.31 (t, *J* = 7.8 Hz, 2H), 7.41 (t, *J* = 7.8 Hz, 2H), 8.31 (s, 1H). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 2.05 (br s, 2H), 3.65-3.80 (m, 3H), 4.36 (s, 1H), 6.83-6.87 (m, 3H), 7.24-7.31 (m, 3H), 7.44-7.45 (m, 4H), 8.22 (s, 1H). ¹³C NMR (150 MHz, CDCl₃) δ: 24.8, 49.1, 49.3, 115.1, 120.2, 120.9, 125.9, 129.7, 129.9, 134.3, 139.3, 145.8, 146.1. HRMS calcd for C₁₇H₁₈N₃O₂: 296.1394 [M+H]⁺, found: 296.1392.

Unfortunately, 1-(4-chlorophenyl)pyrrolidine, 1-(3-chlorophenyl) azepane and *N*-phenylazocane failed to give the expected β-nitrated cyclic enamines, but gave *N*-(4-chlorophenyl)-*N*-(3-(hydroxyimino)-4-oxobutyl)nitrous amide (**I**), *N*-(3-chlorophenyl)-*N*-(6-oxohexyl)nitrous amide (**II**) and *N*-(7-oxoheptyl)-*N*-phenylnitrous amide (**III**) in 25%, 24% and 11% yields, respectively (Scheme S1).



Scheme S1. Formation of I, II and III

A typical procedure for the synthesis of *N*-(4-chlorophenyl)-*N*-(3-(hydroxyimino)-4-oxobutyl) nitrous amide (I)

To a reaction tube equipped with a stir bar were added 1-(4-chlorophenyl)pyrrolidine (**1q**, 36 mg, 0.2 mmol), THF (1 mL), $T^+BF_4^-$ (49 mg, 0.2 mmol), *tert*-butyl nitrite (98%, 73 μ L, 0.6 mmol), 4 Å molecular sieves (100 mg, activated at 500 °C for 5 h before use), and $BF_3 \cdot Et_2O$ (98%, 25 μ L). The resulting mixture was then stirred at room temperature under air for 1 h. Upon completion, the reaction was diluted with ethyl acetate and washed with aqueous NaCl and saturated $NaHCO_3$ solution. The organic layer was dried over anhydrous Na_2SO_4 and filtered. Then, the solvent was evaporated under vacuum and the crude product was purified by column chromatography on silica-gel with petroleum ether/ethyl acetate (5:1) as the eluent to afford **I** as yellow solid in 13 mg (25%).

***N*-(4-Chlorophenyl)-*N*-(3-(hydroxyimino)-4-oxobutyl)nitrous amide (I)³**

Eluent: petroleum ether/ethyl acetate (5:1), yellow solid (13 mg, 25%), m.p.: 144-146 °C. 1H NMR (600 MHz, $DMSO-d_6$) δ : 2.56 (t, $J = 7.2$ Hz, 2H), 4.17 (t, $J = 7.2$ Hz, 2H), 7.61 (s, 4H), 9.33 (s, 1H), 13.14 (s, 1H). ^{13}C NMR (150 MHz, $DMSO-d_6$) δ : 19.4, 39.6, 121.8, 130.0, 132.3, 140.2, 156.9, 191.7.

A typical procedure for the synthesis of *N*-(3-chlorophenyl)-*N*-(6-oxohexyl)nitrous amide (II)

To a reaction tube equipped with a stir bar were added 1-(3-chlorophenyl)azepane (**1r**, 42 mg, 0.2 mmol), THF (1 mL), $T^+BF_4^-$ (49 mg, 0.2 mmol), *tert*-butyl nitrite (98%, 73 μ L, 0.6 mmol), 4 Å molecular sieves (100 mg, activated at 500 °C for 5 h before use), and $BF_3 \cdot Et_2O$ (98%, 25 μ L). The resulting mixture was then stirred at room temperature under air for 1 h. Upon completion, the reaction was diluted with ethyl acetate and washed with aqueous NaCl and saturated $NaHCO_3$ solution. The organic layer was dried over anhydrous Na_2SO_4 and filtered. Then, the solvent was evaporated under vacuum and the crude product was purified by column chromatography on silica-gel with petroleum ether/ethyl acetate (5:1) as the eluent to afford **II** as yellow liquid in 12 mg (24%).

***N*-(3-Chlorophenyl)-*N*-(6-oxohexyl)nitrous amide (II)**

Eluent: petroleum ether/ethyl acetate (5:1), yellow liquid (12 mg, 24%). 1H NMR (400 MHz, $CDCl_3$) δ : 1.30-1.36 (m, 2H), 1.52-1.56 (m, 2H), 1.58-1.67 (m, 2H), 2.42-2.46 (m, 2H), 4.00 (t, $J = 7.6$ Hz, 2H), 7.32-7.35 (m, 1H), 7.41-7.42 (m, 2H), 7.56-7.57 (m, 1H), 9.75 (t, $J = 1.6$ Hz, 1H). ^{13}C NMR (150 MHz, $CDCl_3$) δ : 21.4, 26.3, 26.4, 43.2, 43.6, 117.2, 119.4, 127.3, 130.6, 135.4, 142.5, 202.2. HRMS calcd for $C_{12}H_{16}ClN_2O_2$: 255.0895 $[M+H]^+$, found: 255.0887.

A typical procedure for the synthesis of and *N*-(7-oxoheptyl)-*N*-phenylnitrous amide (III)

To a reaction tube equipped with a stir bar were added 1-phenylazocane (**1s**, 38 mg, 0.2 mmol), THF (1 mL), $T^+BF_4^-$ (49 mg, 0.2 mmol), *tert*-butyl nitrite (98%, 73 μ L, 0.6 mmol), 4 Å molecular sieves (100 mg, activated at 500 °C for 5 h before use), and $BF_3 \cdot Et_2O$ (98%, 25 μ L). The resulting mixture was then stirred at room temperature under air for 1 h. Upon completion, the reaction was diluted with ethyl acetate and washed with aqueous NaCl and saturated $NaHCO_3$ solution. The organic layer was dried over anhydrous Na_2SO_4 and filtered. Then, the solvent was evaporated under vacuum and the crude product was purified by column chromatography on silica-gel with

petroleum ether/ethyl acetate (5:1) as the eluent to afford **III** as yellow liquid in 5 mg (11%).

***N*-(7-Oxoheptyl)-*N*-phenylnitrous amide (**III**)**

Eluent: petroleum ether/ethyl acetate (5:1), yellow liquid (5 mg, 11%). ¹H NMR (600 MHz, CDCl₃) δ: 1.28-1.34 (m, 4H), 1.54-1.64 (m, 4H), 2.41 (t, *J* = 7.2 Hz, 2H), 4.03 (t, *J* = 7.2 Hz, 2H), 7.37 (t, *J* = 7.2 Hz, 1H), 7.47-7.53 (m, 4H), 9.75 (s, 1H). ¹³C NMR (150 MHz, CDCl₃) δ: 21.8, 26.3, 26.8, 28.6, 43.67, 43.70, 119.7, 127.4, 129.6, 141.6, 202.5. HRMS calcd for C₁₃H₁₉N₂O₂: 235.1441 [M+H]⁺, found: 235.1441.

3. A typical procedure for the synthesis of **3a and the spectroscopic data of **3a-3t****

To a reaction tube equipped with a stir bar were added 1-phenylpiperidine (**1a**, 32 mg, 0.2 mmol), acetone (0.5 mL), H₂O (0.5 mL), T⁺BF₄⁻ (97 mg, 0.4 mmol), and *tert*-butyl nitrite (98%, 36 μL, 0.3 mmol). The resulting mixture was then stirred at room temperature under air for 1 h. Upon completion, the reaction was quenched with aqueous NaCl and extracted with ethyl acetate (5 mL × 3). The combined organic layers were dried over anhydrous Na₂SO₄ and filtered. Then, the solvent was evaporated under vacuum and the crude product was purified by column chromatography on silica-gel with petroleum ether/ethyl acetate (20:1) as the eluent to afford **3a** as yellow liquid in 49 mg (68%). **3b-3t** were obtained in an analogous manner.

1 mmol scale procedure for the synthesis of **3a**

To a reaction tube equipped with a stir bar were added 1-phenylpiperidine (**1a**, 161 mg, 1 mmol), acetone (2.5 mL), H₂O (2.5 mL), T⁺BF₄⁻ (486 mg, 2 mmol), and *tert*-butyl nitrite (98%, 182 μL, 1.5 mmol). The resulting mixture was then stirred at room temperature under air for 1 h. Upon completion, the reaction was quenched with aqueous NaCl and extracted with ethyl acetate (20 mL × 3). The combined organic layers were dried over anhydrous Na₂SO₄ and filtered. Then, the solvent was evaporated under vacuum and the crude product was purified by column

chromatography on silica-gel with petroleum ether/ethyl acetate (20:1) as the eluent to afford **3a** as yellow liquid in 224 mg (62%).

***N*-(5-Oxo-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)pentyl)-*N*-phenylnitrous amide (3a)**

Eluent: petroleum ether/ethyl acetate (20:1), Yellow liquid (49 mg, 68%). ¹H NMR (400 MHz, CDCl₃) δ: 1.11-1.13 (m, 12H), 1.32-1.44 (m, 5H), 1.58-1.74 (m, 5H), 4.02-4.12 (m, 3H), 7.35-7.39 (m, 1H), 7.45-7.53 (m, 4H), 9.79 (d, *J* = 3.6 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 17.1, 20.3, 20.4, 21.6, 27.4, 33.9, 34.2, 40.0, 40.1, 43.4, 60.0, 60.6, 87.6, 119.6, 127.5, 129.6, 141.3, 204.3. HRMS calcd for C₂₀H₃₂N₃O₃: 362.2438 [M+H]⁺, found: 362.2438.

***N*-(4-Fluorophenyl)-*N*-(5-oxo-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)pentyl)nitrous amide (3b)**

Eluent: petroleum ether/ethyl acetate (20:1), Yellow solid (48 mg, 63%), m.p.: 40-41 °C H NMR (400 MHz, CDCl₃) δ: 1.11-1.13 (m, 12H), 1.45-1.48 (m, 5H), 1.56-1.73 (m, 5H), 3.99-4.11 (m, 3H), 7.16-7.20 (m, 2H), 7.46-7.50 (m, 2H), 9.80 (d, *J* = 4.0 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 17.1, 20.3, 20.4, 21.6, 27.4, 33.8, 34.2, 40.1, 43.7, 60.0, 60.5, 87.6, 116.5 (d, ²*J*_{C-F} = 22.4 Hz), 121.7 (d, ³*J*_{C-F} = 7.9 Hz), 137.6 (d, ⁴*J*_{C-F} = 3.6 Hz), 161.9 (d, ¹*J*_{C-F} = 231.9 Hz), 204.2. ¹⁹F NMR (376 MHz, CDCl₃) δ: -114.4. HRMS calcd for C₂₀H₃₁FN₃O₃: 380.2344 [M+H]⁺, found: 380.2345.

***N*-(4-Chlorophenyl)-*N*-(5-oxo-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)pentyl)nitrous amide (3c)**

Eluent: petroleum ether/ethyl acetate (20:1), Yellow solid (59 mg, 75%), m.p.: 79-80 °C H NMR (400 MHz, CDCl₃) δ: 1.11-1.13 (m, 12H), 1.30-1.33 (m, 1H), 1.45-1.48 (m, 4H), 1.54-1.75 (m, 5H), 3.99-4.12 (m, 3H), 7.16-7.20 (m, 2H), 7.46-7.50 (m, 2H), 9.80 (d, *J* = 4.0 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 17.1, 20.3, 20.4, 21.6, 27.4, 33.9, 34.2, 40.1, 43.1, 60.0, 60.6, 87.6, 120.5, 129.8, 133.1, 139.9, 204.2. HRMS calcd for C₂₀H₃₁ClN₃O₃: 396.2048 [M+H]⁺, found: 396.2057.

***N*-(4-Bromophenyl)-*N*-(5-oxo-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)pentyl)nitrous amide (3d)**

Eluent: petroleum ether/ethyl acetate (20:1), Yellow solid (64 mg, 73%), m.p.: 64-65 °C H NMR (400 MHz, CDCl₃) δ: 1.11-1.13 (m, 12H), 1.31-1.33 (m, 1H), 1.45-1.47 (m, 4H), 1.54-1.73 (m, 5H), 3.98-4.12 (m, 3H), 7.39-7.43 (m, 2H), 7.58-7.62 (m, 2H), 9.80 (d, *J* = 3.6 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 17.0, 20.3, 20.4, 21.6, 27.4, 33.9, 34.2, 40.1, 43.0, 60.0, 60.6, 87.5, 120.75, 120.82, 132.7, 140.4, 204.2. HRMS calcd for C₂₀H₃₁BrN₃O₃: 440.1543 [M+H]⁺, found: 440.1538.

***N*-(4-Cyanophenyl)-*N*-(5-oxo-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)pentyl)nitrous amide (3e)**

Eluent: petroleum ether/ethyl acetate (20:1), Yellow liquid (49 mg, 63%). H NMR (400 MHz, CDCl₃) δ: 1.12-1.14 (m, 12H), 1.34-1.46 (m, 5H), 1.54-1.75 (m, 5H), 3.99-4.15 (m, 3H), 7.70 (dd, *J*₁ = 7.2 Hz, *J*₂ = 1.6 Hz, 2H), 7.79 (dd, *J*₁ = 7.2 Hz, *J*₂ = 2.0 Hz, 2H), 9.82 (d, *J* = 3.6 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 17.0, 20.3, 20.4, 21.5, 27.3, 33.9, 34.2, 40.1, 42.2, 60.0, 60.6, 87.5, 110.4, 118.2, 118.3, 133.7, 144.7, 204.1. HRMS calcd for C₂₁H₃₁N₄O₃: 387.2391 [M+H]⁺, found: 387.2387.

***N*-(5-Oxo-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)pentyl)-*N*-(*p*-tolyl)nitrous amide (3f)**

Eluent: petroleum ether/ethyl acetate (20:1), Yellow liquid (31 mg, 41%). ¹H NMR (400 MHz, CDCl₃) δ: 1.11-1.13 (m, 12H), 1.25-1.44 (m, 5H), 1.57-1.73 (m, 5H), 2.40 (s, 3H), 4.00-4.09 (m, 3H), 7.27 (d, *J* = 7.2 Hz, 2H), 7.37-7.40 (m, 2H), 9.79 (d, *J* = 4.0 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 17.1, 20.3, 20.4, 21.0, 21.6, 27.5, 33.9, 34.2, 40.1, 43.6, 60.0, 60.6, 87.6, 119.8, 130.1, 137.5, 139.0, 204.2. HRMS calcd for C₂₁H₃₄N₃O₃: 376.2595 [M+H]⁺, found: 376.2590.

***N*-(5-Oxo-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)pentyl)-*N*-(*m*-tolyl)nitrous amide (3g)**

Eluent: petroleum ether/ethyl acetate (20:1), Yellow liquid (30 mg, 40%). H NMR (400 MHz,

CDCl₃) δ : 1.11-1.13 (m, 12H), 1.32-1.44 (m, 5H), 1.56-1.75 (m, 5H), 2.43 (s, 3H), 4.01-4.11 (m, 3H), 7.18 (t, $J = 8.0$ Hz, 1H), 7.28-7.37 (m, 3H), 9.79 (d, $J = 4.0$ Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ : 17.1, 20.3, 20.4, 21.5, 21.6, 27.5, 33.9, 34.2, 40.1, 43.5, 60.0, 60.6, 87.6, 116.8, 120.5, 128.3, 129.4, 139.7, 141.3, 204.2. HRMS calcd for C₂₁H₃₄N₃O₃: 376.2595 [M+H]⁺, found: 376.2593.

***N*-(3-Fluorophenyl)-*N*-(5-oxo-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)pentyl)nitrous amide (3h)**

Eluent: petroleum ether/ethyl acetate (20:1), Yellow solid (47 mg, 62%), m.p.: 55-56 °C H NMR (400 MHz, CDCl₃) δ : 1.12-1.14 (m, 12H), 1.32-1.45 (m, 5H), 1.58-1.73 (m, 5H), 3.99-4.13 (m, 3H), 7.04-7.08 (m, 1H), 7.28-7.35 (m, 2H), 7.42-7.47 (m, 1H), 9.81 (d, $J = 3.6$ Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ : 17.0, 20.3, 20.4, 21.6, 27.4, 33.9, 34.2, 40.1, 42.9, 60.0, 60.6, 87.6, 106.6 (d, ² $J_{C-F} = 26.0$ Hz), 114.0 (d, ² $J_{C-F} = 21.0$ Hz), 114.3 (d, ⁴ $J_{C-F} = 3.6$ Hz), 130.9 (d, ³ $J_{C-F} = 9.4$ Hz), 142.8 (d, ³ $J_{C-F} = 10.1$ Hz), 163.2 (d, ¹ $J_{C-F} = 246.3$ Hz), 204.1. ¹⁹F NMR (376 MHz, CDCl₃) δ : -110.3. HRMS calcd for C₂₀H₃₁FN₃O₃: 380.2344 [M+H]⁺, found: 380.2337.

***N*-(3-Chlorophenyl)-*N*-(5-oxo-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)pentyl)nitrous amide (3i)**

Eluent: petroleum ether/ethyl acetate (20:1), Yellow liquid (60 mg, 76%). H NMR (400 MHz, CDCl₃) δ : 1.12-1.14 (m, 12H), 1.30-1.47 (m, 5H), 1.54-1.76 (m, 5H), 3.99-4.13 (m, 3H), 7.32-7.39 (m, 1H), 7.41-7.42 (m, 2H), 7.57 (d, $J = 0.8$ Hz, 1H), 9.81 (d, $J = 3.6$ Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ : 17.1, 20.3, 20.4, 21.6, 27.4, 33.9, 34.2, 40.1, 43.0, 60.0, 60.6, 87.6, 117.2, 119.4, 127.3, 130.6, 135.5, 142.4, 204.2. HRMS calcd for C₂₀H₃₁ClN₃O₃: 396.2048 [M+H]⁺, found: 396.2040.

***N*-(3-Bromophenyl)-*N*-(5-oxo-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)pentyl)nitrous amide (3j)**

Eluent: petroleum ether/ethyl acetate (20:1), Yellow liquid (54 mg, 61%). H NMR (400 MHz, CDCl₃) δ: 1.12-1.14 (m, 12H), 1.29-1.45 (m, 5H), 1.58-1.72 (m, 5H), 3.98-4.12 (m, 3H), 7.35 (t, *J* = 8.0 Hz, 1H), 7.45-7.51 (m, 2H), 7.73 (t, *J* = 2.0 Hz, 1H), 9.81 (d, *J* = 4.0 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 17.1, 20.3, 20.4, 21.6, 27.4, 33.9, 34.2, 40.06, 40.10, 43.0, 60.0, 60.6, 87.6, 117.7, 122.3, 123.3, 130.2, 130.9, 142.5, 204.3. HRMS calcd for C₂₀H₃₁BrN₃O₃: 440.1543 [M+H]⁺, found: 440.1541.

***N*-(3-Nitrophenyl)-*N*-(5-oxo-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)pentyl)nitrous amide (3k)**

Eluent: petroleum ether/ethyl acetate (20:1), Yellow liquid (37 mg, 46%). H NMR (400 MHz, CDCl₃) δ: 1.12-1.14 (m, 12H), 1.26-1.45 (m, 5H), 1.56-1.78 (m, 5H), 4.07-4.15 (m, 3H), 7.69 (t, *J* = 8.0 Hz, 1H), 7.93-7.95 (m, 1H), 8.22 (dd, *J*₁ = 8.0 Hz, *J*₂ = 1.6 Hz, 1H), 8.41 (t, *J* = 2.0 Hz, 1H), 9.83 (d, *J* = 3.6 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 17.0, 20.3, 20.4, 21.6, 27.3, 33.9, 34.2, 40.1, 42.7, 60.0, 60.6, 87.5, 113.4, 121.5, 124.2, 130.6, 142.4, 149.0, 204.1. HRMS calcd for C₂₀H₃₁N₄O₅: 407.2289 [M+H]⁺, found: 407.2283.

***N*-([1,1'-Biphenyl]-4-yl)-*N*-(5-oxo-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)pentyl)nitrous amide (3l)**

Eluent: petroleum ether/ethyl acetate (20:1), Yellow solid (44 mg, 50%), m.p.: 84-85 °C H NMR (400 MHz, CDCl₃) δ: 1.12 (s, 12H), 1.32-1.47 (m, 5H), 1.62-1.78 (m, 5H), 4.05-4.14 (m, 3H), 7.36-7.40 (m, 1H), 7.45-7.49 (m, 2H), 7.58-7.63 (m, 4H), 7.68-7.71 (m, 2H), 9.81 (d, *J* = 4.0 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 17.1, 20.3, 20.4, 21.7, 27.5, 33.9, 34.3, 40.0, 40.1, 43.3, 60.0, 60.6, 87.6, 119.7, 127.0, 127.8, 128.2, 129.0, 139.9, 140.35, 140.44, 204.3. HRMS calcd for C₂₆H₃₆N₃O₃: 438.2751 [M+H]⁺, found: 438.2746.

***N*-(4-Fluorophenyl)-*N*-(3-methyl-5-oxo-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)pentyl)nitrou**

s amide (3m)

Eluent: petroleum ether/ethyl acetate (20:1), Yellow liquid (48 mg, 61%). H NMR (400 MHz, CDCl₃) δ: 1.06 (d, *J* = 6.8 Hz, 3H), 1.13 (s, 12H), 1.29-2.05 (m, 9H), 3.96-4.02 (m, 2H), 4.16-4.20 (m, 1H), 7.16-7.20 (m, 2H), 7.47-7.51 (m, 2H), 9.93 (d, *J* = 4.8 Hz, 1H). ¹³C NMR (150 MHz, CDCl₃) δ: 15.5, 17.0, 20.4, 20.5, 28.7, 34.0, 34.1, 34.3, 40.2, 40.3, 42.3, 60.0, 61.1, 90.4, 116.5 (d, ²*J*_{C-F} = 18.6 Hz), 121.6 (d, ³*J*_{C-F} = 7.7 Hz), 137.6 (d, ⁴*J*_{C-F} = 2.3 Hz), 161.8 (d, ¹*J*_{C-F} = 247.2 Hz), 205.1. ¹⁹F NMR (565 MHz, CDCl₃) δ: -114.4. HRMS calcd for C₂₁H₃₃FN₃O₃: 394.2500 [M+H]⁺, found: 394.2495.

***N*-(4-Methoxyphenyl)-*N*-(3-methyl-5-oxo-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)pentyl)nitrous amide (3n)**

Eluent: petroleum ether/ethyl acetate (20:1), Yellow liquid (22 mg, 27%). H NMR (400 MHz, CDCl₃) δ: 1.05 (d, *J* = 6.8 Hz, 3H), 1.14 (s, 12H), 1.27-1.58 (m, 7H), 1.78-1.81 (m, 1H), 2.02-2.06 (m, 1H), 3.86 (s, 3H), 3.95-4.03 (m, 2H), 4.17-4.23 (m, 1H), 6.97-7.01 (m, 2H), 7.39-7.43 (m, 2H), 9.92 (d, *J* = 4.8 Hz, 1H). ¹³C NMR (150 MHz, CDCl₃) δ: 15.5, 17.1, 20.45, 20.54, 28.8, 34.0, 34.1, 34.3, 40.2, 40.3, 42.7, 55.6, 60.1, 90.5, 114.7, 121.8, 134.6, 159.1, 205.2. HRMS calcd for C₂₂H₃₆N₃O₄: 406.2700 [M+H]⁺, found: 406.2696.

***N*-(3-Chlorophenyl)-*N*-(3-methyl-5-oxo-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)pentyl)nitrous amide (3o)**

Eluent: petroleum ether/ethyl acetate (20:1), Yellow liquid (47 mg, 57%). H NMR (400 MHz, CDCl₃) δ: 1.07 (d, *J* = 6.8 Hz, 3H), 1.14 (s, 12H), 1.35-1.54 (m, 7H), 1.80-1.83 (m, 1H), 2.05-2.09 (m, 1H), 3.97-4.02 (m, 2H), 4.17-4.22 (m, 1H), 7.32-7.36 (m, 1H), 7.39-7.44 (m, 2H), 7.58-7.59 (m, 1H), 9.94 (d, *J* = 4.4 Hz, 1H). ¹³C NMR (150 MHz, CDCl₃) δ: 15.5, 17.0, 20.4, 20.5, 28.7, 34.0, 34.1, 34.3, 40.17, 40.25, 41.6, 60.1, 61.0, 90.5, 117.0, 119.3, 127.2, 130.6, 135.5, 142.4, 205.1.

HRMS calcd for C₂₁H₃₃ClN₃O₃: 410.2205 [M+H]⁺, found: 410.2208.

***N*-(6-Oxo-5-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)hexyl)-*N*-phenylnitrous amide (3p)**

Eluent: petroleum ether/ethyl acetate (20:1), Yellow liquid (26 mg, 35%). H NMR (600 MHz, CDCl₃) δ: 1.12-1.13 (m, 12H), 1.31-1.74 (m, 12H), 4.00-4.07 (m, 3H), 7.37 (t, *J* = 7.2 Hz, 1H), 7.46-7.52 (m, 4H), 9.77 (d, *J* = 4.2 Hz, 1H). ¹³C NMR (150 MHz, CDCl₃) δ: 17.1, 20.3, 20.4, 22.0, 26.5, 29.5, 33.9, 34.3, 40.1, 43.6, 59.8, 60.6, 88.0, 119.8, 127.4, 129.6, 141.5, 204.4. HRMS calcd for C₂₁H₃₄N₃O₃: 376.2595 [M+H]⁺, found: 376.2588.

***N*-(4-Methoxyphenyl)-*N*-(6-oxo-5-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)hexyl)nitrous amide (3q)**

Eluent: petroleum ether/ethyl acetate (20:1), Yellow liquid (16 mg, 20%). H NMR (600 MHz, CDCl₃) δ: 1.12-1.13 (m, 12H), 1.30-1.73 (m, 12H), 3.86 (s, 3H), 3.97-4.06 (m, 3H), 6.99 (d, *J* = 8.4 Hz, 2H), 7.39 (d, *J* = 8.4 Hz, 2H), 9.77 (d, *J* = 4.2 Hz, 1H). ¹³C NMR (150 MHz, CDCl₃) δ: 17.1, 20.3, 20.4, 21.9, 26.4, 29.5, 33.9, 34.3, 40.1, 44.2, 55.6, 59.8, 60.6, 88.1, 114.7, 122.0, 134.8, 159.1, 204.5. HRMS calcd for C₂₂H₃₆N₃O₄: 406.2700 [M+H]⁺, found: 406.2694.

***N*-(4-Fluorophenyl)-*N*-(6-oxo-5-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)hexyl)nitrous amide (3r)**

Eluent: petroleum ether/ethyl acetate (20:1), Yellow liquid (32 mg, 41%). H NMR (400 MHz, CDCl₃) δ: 1.12-1.13 (m, 12H), 1.28-1.63 (m, 12H), 3.97-4.07 (m, 3H), 7.16-7.20 (m, 2H), 7.45-7.49 (m, 2H), 9.78 (d, *J* = 4.0 Hz, 1H). ¹³C NMR (150 MHz, CDCl₃) δ: 17.1, 20.3, 20.4, 21.9, 26.4, 29.4, 29.7, 33.9, 34.3, 40.1, 43.9, 59.9, 60.6, 88.0, 116.5 (d, ²*J*_{C-F} = 23.0 Hz), 121.8 (d, ³*J*_{C-F} = 7.7 Hz), 137.7 (d, ⁴*J*_{C-F} = 3.3 Hz), 161.8 (d, ¹*J*_{C-F} = 246.2 Hz), 204.4. ¹⁹F NMR (376 MHz, CDCl₃) δ: -114.4. HRMS calcd for C₂₁H₃₃FN₃O₃: 394.2500 [M+H]⁺, found: 394.2483.

***N*-(3-Fluorophenyl)-*N*-(6-oxo-5-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)hexyl)nitrous amide**

(3s)

Eluent: petroleum ether/ethyl acetate (20:1), Yellow liquid (28 mg, 36%). H NMR (400 MHz, CDCl₃) δ : 1.12-1.14 (m, 12H), 1.29-1.74 (m, 12H), 3.98-4.08 (m, 3H), 7.06-7.08 (m, 1H), 7.28-7.33 (m, 2H), 7.41-7.45 (m, 1H), 9.79 (d, $J = 4.0$ Hz, 1H). ¹³C NMR (150 MHz, CDCl₃) δ : 17.1, 20.3, 20.4, 21.9, 26.4, 29.4, 29.7, 33.9, 34.3, 40.1, 43.1, 59.8, 60.6, 88.0, 106.8 (d, ² $J_{C-F} = 26.3$ Hz), 114.0 (d, ² $J_{C-F} = 20.9$ Hz), 114.5 (d, ⁴ $J_{C-F} = 3.3$ Hz), 130.9 (d, ³ $J_{C-F} = 9.9$ Hz), 143.0 (d, ³ $J_{C-F} = 9.9$ Hz), 163.3 (d, ¹ $J_{C-F} = 246.2$ Hz), 204.4. ¹⁹F NMR (376 MHz, CDCl₃) δ : -110.3. HRMS calcd for C₂₁H₃₃FN₃O₃: 394.2500 [M+H]⁺, found: 394.2491.

***N*-(7-Oxo-6-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)heptyl)-*N*-phenylnitrous amide (3t)**

Eluent: petroleum ether/ethyl acetate (20:1), Yellow liquid (16 mg, 21%). H NMR (600 MHz, CDCl₃) δ : 1.12-1.14 (m, 12H), 1.28-1.71 (m, 14H), 4.00-4.06 (m, 3H), 7.37 (t, $J = 7.2$ Hz, 1H), 7.46-7.53 (m, 4H), 9.77 (d, $J = 4.2$ Hz, 1H). ¹³C NMR (150 MHz, CDCl₃) δ : 17.1, 20.3, 20.4, 23.9, 26.3, 27.1, 29.7, 29.8, 33.8, 34.3, 40.1, 43.7, 59.8, 60.5, 88.3, 119.7, 127.4, 129.6, 141.6, 204.6. HRMS calcd for C₂₂H₃₆N₃O₃: 390.2751 [M+H]⁺, found: 390.2749.

4. A typical procedure for the synthesis of 4a and the spectroscopic data of 4b-4d

To a reaction tube equipped with a stir bar were added *N*-(5-oxo-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)pentyl)-*N*-phenylnitrous amide (**3a**, 72 mg, 0.2 mmol), THF (2 mL), activated zinc powder (52 mg, 0.8 mmol) and NH₄Cl (32 mg, 0.6 mmol). The mixture was stirred at 50 °C for 4 h. Subsequently, activated zinc powder (52 mg, 0.8 mmol), NH₄Cl (32 mg, 0.6 mmol) and H₂O (2 mL) were added to the reaction mixture, and stirred at 50 °C for 4 h. Then, activated zinc powder (52 mg, 0.8 mmol) and NH₄Cl (32 mg, 0.6 mmol) were added to the reaction mixture, and stirred at 50 °C for another 4 h. Upon completion, the mixture was cooled to room temperature. The precipitate was filtered and the remaining mixture was then

extracted with CH₂Cl₂ (10 mL × 3). The combined organic layers were washed with saturated brine solution, dried over anhydrous Na₂SO₄, filtrated, and the solvent was evaporated under vacuum. The crude product was purified by column chromatography on silica-gel with petroleum ether/ethyl acetate (20:1) as the eluent to afford **4a** as yellow liquid in 41 mg (62%). **4b-4d** were obtained in an analogous manner.

1 mmol scale procedure for the synthesis of 4a

To a reaction tube equipped with a stir bar were added *N*-(5-oxo-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)pentyl)-*N*-phenylnitrous amide (**3a**, 361 mg, 1 mmol), THF (20 mL), activated zinc powder (262 mg, 4 mmol) and NH₄Cl (160 mg, 3 mmol). The mixture was stirred at 50 °C for 4 h. Subsequently, activated zinc powder (262 mg, 4 mmol), NH₄Cl (160 mg, 3 mmol) and H₂O (20 mL) were added to the reaction mixture, and stirred at 50 °C for 4 h. Then, activated zinc powder (262 mg, 4 mmol) and NH₄Cl (160 mg, 3 mmol) were added to the reaction mixture, and stirred at 50 °C for another 4 h. Upon completion, the mixture was cooled to room temperature. The precipitate was filtered and the remaining mixture was the extracted with CH₂Cl₂ (20 mL × 3). The combined organic layers were washed with saturated brine solution, dried over anhydrous Na₂SO₄, filtrated, and the solvent was evaporated under vacuum. The crude product was purified by column chromatography on silica-gel with petroleum ether/ethyl acetate (20:1) as the eluent to afford **4a** as yellow liquid in 184 mg (56%).

1-Phenyl-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4,5,6,7-tetrahydro-1*H*-1,2-diazepine (4a)

Eluent: petroleum ether/ethyl acetate (20:1); Yellow liquid (41 mg, 62%). ¹H NMR (600 MHz, CDCl₃) δ: 1.14-1.21 (m, 12H), 1.47-1.56 (m, 6H), 1.74-1.77 (m, 1H), 1.90-1.97 (m, 2H), 2.08-2.11 (m, 1H), 3.28-3.33 (m, 1H), 3.89-3.93 (m, 1H), 4.53-4.56 (m, 1H), 6.88 (t, *J* = 7.2 Hz, 1H), 7.17 (d, *J* = 7.8 Hz, 2H), 7.26-7.29 (m, 3H). ¹³C NMR (150 MHz, CDCl₃) δ: 17.2, 20.3, 20.5, 25.8, 27.7,

34.0, 34.8, 40.2, 53.7, 59.9, 81.8, 114.9, 120.2, 128.9, 150.3, 151.6. HRMS calcd for C₂₀H₃₂N₃O: 330.2540 [M+H]⁺, found: 330.2540.

1-(4-Fluorophenyl)-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4,5,6,7-tetrahydro-1H-1,2-diazepine (4b)

Eluent: petroleum ether/ethyl acetate (20:1); Yellow liquid (35 mg, 50%). ¹H NMR (600 MHz, CDCl₃) δ: 1.14-1.33 (m, 12H), 1.48-1.57 (m, 6H), 1.69-1.73 (m, 1H), 1.89-1.95 (m, 2H), 2.09-2.12 (m, 1H), 3.21-3.25 (m, 1H), 3.77-3.80 (m, 1H), 4.53-4.55 (m, 1H), 6.94-6.97 (m, 2H), 7.12-7.14 (m, 2H), 7.28 (d, *J* = 3.6 Hz, 1H). ¹³C NMR (150 MHz, CDCl₃) δ: 17.2, 20.3, 20.5, 26.0, 27.6, 34.0, 34.7, 40.2, 54.8, 59.9, 81.8, 115.2 (d, ²*J*_{C-F} = 23.0 Hz), 116.8 (d, ³*J*_{C-F} = 7.7 Hz), 147.4, 152.1, 157.7 (d, ¹*J*_{C-F} = 237.3 Hz). ¹⁹F NMR (565 MHz, CDCl₃) δ: -124.5. HRMS calcd for C₂₀H₃₁FN₃O: 348.2446 [M+H]⁺, found: 348.2447.

1-(4-Bromophenyl)-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4,5,6,7-tetrahydro-1H-1,2-diazepine (4c)

Eluent: petroleum ether/ethyl acetate (20:1); Yellow liquid (49 mg, 60%). ¹H NMR (400 MHz, CDCl₃) δ: 1.14-1.18 (m, 12H), 1.48-1.57 (m, 6H), 1.74-1.78 (m, 1H), 1.91-1.95 (m, 2H), 2.07-2.09 (m, 1H), 3.26-3.33 (m, 1H), 3.81-3.86 (m, 1H), 4.51-4.55 (m, 1H), 7.03-7.06 (m, 2H), 7.30 (d, *J* = 3.6 Hz, 1H), 7.32-7.35 (m, 2H). ¹³C NMR (150 MHz, CDCl₃) δ: 17.2, 20.3, 20.5, 25.5, 27.6, 34.0, 34.8, 40.2, 53.7, 59.9, 81.7, 112.4, 116.4, 131.6, 149.3, 152.5. HRMS calcd for C₂₀H₃₁BrN₃O: 408.1645 [M+H]⁺, found: 408.1646.

1-(3-Chlorophenyl)-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4,5,6,7-tetrahydro-1H-1,2-diazepine (4d)

Eluent: petroleum ether/ethyl acetate (20:1); Yellow liquid (46 mg, 63%). ¹H NMR (600 MHz, CDCl₃) δ: 1.13-1.34 (m, 12H), 1.48-1.58 (m, 6H), 1.74-1.79 (m, 1H), 1.88-1.97 (m, 2H), 2.06-2.09

(m, 1H), 3.29-3.34 (m, 1H), 3.84-3.88 (m, 1H), 4.52-4.54 (m, 1H), 6.83-6.84 (m, 1H), 6.99 (dd, $J_1 = 7.8$ Hz, $J_2 = 1.2$ Hz, 1H), 7.15-7.19 (m, 2H), 7.31 (d, $J = 4.2$ Hz, 1H). ^{13}C NMR (150 MHz, CDCl_3) δ : 17.7, 20.3, 20.5, 25.5, 27.6, 34.0, 34.8, 40.2, 53.5, 59.9, 81.7, 112.6, 114.7, 119.9, 129.8, 134.8, 151.2, 152.7. HRMS calcd for $\text{C}_{20}\text{H}_{31}\text{ClN}_3\text{O}$: 364.2150 $[\text{M}+\text{H}]^+$, found: 364.2164.

5. A typical procedure for the synthesis of 5a and the spectroscopic data of 5b-5d

To a reaction tube equipped with a stir bar were added *N*-(5-oxo-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)pentyl)-*N*-phenylnitrous amide (**3a**, 72 mg, 0.2 mmol), AcOH/THF/ H_2O (1:1:1.5, 7 mL), and zinc powder (523 mg, 8 mmol). The mixture was then stirred at 70 °C for 20 min. Upon completion, the mixture was cooled to room temperature. The precipitate was filtered and the remaining mixture was extracted with EtOAc (10 mL \times 3). The combined organic layers were washed with saturated brine solution and saturated NaHCO_3 solution, dried over anhydrous Na_2SO_4 , filtrated, and the solvent was evaporated under vacuum. The crude product was purified by column chromatography on silica-gel with petroleum ether/ethyl acetate (5:1) as the eluent to afford **5a** as yellow liquid in 23 mg (60%). **5b-5d** were obtained in an analogous manner.

1 mmol scale procedure for the synthesis of 5a

To a reaction tube equipped with a stir bar were added *N*-(5-oxo-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)pentyl)-*N*-phenylnitrous amide (**3a**, 361 mg, 1 mmol), AcOH/THF/ H_2O (1:1:1.5, 35 mL), and zinc powder (2.62 g, 40 mmol). The mixture was then stirred at 70 °C for 20 min. Upon completion, the mixture was cooled to room temperature. The precipitate was filtered and the remaining mixture was extracted with EtOAc (20 mL \times 3). The combined organic layers were washed with saturated brine solution and saturated NaHCO_3 solution, dried over anhydrous Na_2SO_4 , filtrated, and the solvent was evaporated under vacuum.

The crude product was purified by column chromatography on silica-gel with petroleum ether/ethyl acetate (5:1) as the eluent to afford **5a** as yellow liquid in 106 mg (56%).

1-Phenyl-4,5,6,7-tetrahydro-1H-1,2-diazepin-4-ol (5a)

Eluent: petroleum ether/ethyl acetate (5:1); Yellow liquid (23 mg, 60%). ¹H NMR (600 MHz, CDCl₃) δ: 1.57-1.75 (m, 2H), 1.88-1.96 (m, 2H), 2.02-2.06 (m, 1H), 3.14-3.18 (m, 1H), 3.84-3.88 (m, 1H), 4.56-4.57 (m, 1H), 6.92 (t, *J* = 7.2 Hz, 1H), 7.12 (s, 1H), 7.19 (d, *J* = 8.4 Hz, 2H), 7.26-7.29 (m, 2H). ¹³C NMR (150 MHz, CDCl₃) δ: 26.2, 31.3, 54.9, 71.3, 115.5, 120.9, 128.9, 150.7, 154.5. HRMS calcd for C₁₁H₁₅N₂O: 191.1179 [M+H]⁺, found: 191.1162.

1-(4-Fluorophenyl)-4,5,6,7-tetrahydro-1H-1,2-diazepin-4-ol (5b)

Eluent: petroleum ether/ethyl acetate (5:1); Yellow liquid (27 mg, 65%). ¹H NMR (400 MHz, CDCl₃) δ: 1.64-1.71 (m, 1H), 1.87-2.03 (m, 4H), 3.02-3.08 (m, 1H), 3.71-3.77 (m, 1H), 4.51-4.54 (m, 1H), 6.94-6.99 (m, 2H), 7.11-7.16 (m, 3H). ¹³C NMR (150 MHz, CDCl₃) δ: 26.4, 31.2, 56.0, 71.2, 115.3 (d, ²*J*_{C-F} = 21.8 Hz), 117.8 (d, ³*J*_{C-F} = 7.7 Hz), 147.8 (d, ⁴*J*_{C-F} = 2.3 Hz), 155.2, 158.0 (d, ¹*J*_{C-F} = 237.3 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ: -123.4. HRMS calcd for C₁₁H₁₄FN₂O: 209.1085 [M+H]⁺, found: 209.1087.

1-(4-Bromophenyl)-4,5,6,7-tetrahydro-1H-1,2-diazepin-4-ol (5c)

Eluent: petroleum ether/ethyl acetate (5:1); Colorless liquid (37 mg, 69%). ¹H NMR (400 MHz, CDCl₃) δ: 1.67-1.76 (m, 2H), 1.88-2.07 (m, 3H), 3.09-3.16 (m, 1H), 3.77-3.84 (m, 1H), 4.53-4.57 (m, 1H), 7.04-7.07 (m, 2H), 7.13 (d, *J* = 1.6 Hz, 1H), 7.33-7.37 (m, 2H). ¹³C NMR (150 MHz, CDCl₃) δ: 26.1, 31.2, 54.9, 71.2, 113.1, 117.0, 131.7, 149.7, 155.3. ¹H NMR (600 MHz, DMSO-*d*₆) δ: 1.53-1.55 (m, 1H), 1.77-1.83 (m, 2H), 1.90-1.92 (m, 1H), 3.06-3.10 (m, 1H), 3.82-3.86 (m, 1H), 4.35-4.37 (m, 1H), 5.52 (d, *J* = 5.4 Hz, 1H), 7.01 (s, 1H), 7.10 (d, *J* = 8.4 Hz, 2H), 7.36 (d, *J* = 8.4 Hz, 2H). ¹³C NMR (150 MHz, DMSO-*d*₆) δ: 25.9, 31.4, 54.3, 70.2, 111.5, 117.0, 131.8, 149.9,

157.4. HRMS calcd for C₁₁H₁₄BrN₂O: 269.0284 [M+H]⁺, found: 269.0270.

1-(3-Chlorophenyl)-4,5,6,7-tetrahydro-1H-1,2-diazepin-4-ol (**5d**)

Eluent: petroleum ether/ethyl acetate (5:1); Yellow liquid (26 mg, 58%). ¹H NMR (400 MHz, CDCl₃) δ: 1.58-1.77 (m, 2H), 1.88-2.06 (m, 3H), 3.12-3.19 (m, 1H), 3.81-3.87 (m, 1H), 4.54-4.57 (m, 1H), 6.86-6.88 (m, 1H), 7.01 (dd, *J*₁ = 8.4 Hz, *J*₂ = 1.6 Hz, 1H), 7.14-7.21 (m, 3H). ¹³C NMR (150 MHz, CDCl₃) δ: 26.0, 31.2, 54.6, 71.2, 113.2, 115.4, 120.5, 129.9, 134.8, 151.6, 155.7. HRMS calcd for C₁₁H₁₃ClN₂ONa: 247.0609 [M+Na]⁺, found: 247.0611.

6. Control Experiments

6.1. To a reaction tube equipped with a stir bar were added 1-phenylpiperidine (**1a**, 32 mg, 0.2 mmol), THF (1 mL), T⁺BF₄⁻ (49 mg, 0.2 mmol), *tert*-butyl nitrite (98%, 73 μL, 0.6 mmol), 4 Å molecular sieves (100 mg, activated at 500 °C for 5 h before use), BF₃·Et₂O (98%, 25 μL), and BHT (88 mg, 0.4 mmol). The resulting mixture was then stirred at room temperature under air for 1 h. Subsequent TLC analysis of the resulting mixture showed that there was no desired product **2a** formed from this reaction.

6.2. To a reaction tube equipped with a stir bar were added 1-phenylpiperidine (**1a**, 32 mg, 0.2 mmol), acetone (0.5 mL), H₂O (0.5 mL), T⁺BF₄⁻ (97 mg, 0.4 mmol), *tert*-butyl nitrite (98%, 36 μL, 0.3 mmol), and BHT (88 mg, 0.4 mmol). The resulting mixture was then stirred at room temperature under air for 1 h. Upon completion, the reaction was quenched with aqueous NaCl and extracted with ethyl acetate (5 mL × 3). The combined organic layers were dried over anhydrous Na₂SO₄ and filtered. Then, the solvent was evaporated under vacuum and the crude product was purified by column chromatography on silica-gel with petroleum ether/ethyl acetate (20:1) as the eluent to afford **3a** as yellow liquid in 46 mg (64%).


6.3. To a reaction tube equipped with a stir bar were added 1-phenylpiperidine (**1a**, 32 mg, 0.2


mmol), THF (1 mL), $T^+BF_4^-$ (49 mg, 0.2 mmol), *tert*-butyl nitrite (98%, 73 μ L, 0.6 mmol), 4 Å molecular sieves (100 mg, activated at 500 °C for 5 h before use), and $BF_3 \cdot Et_2O$ (98%, 25 μ L). It was then stirred at room temperature for 15 min. Subsequent HRMS analysis of the resulting mixture showed that enamine (**B**) (calcd, 182.0940; found, 182.0949) was formed.

6.4. To a reaction tube equipped with a stir bar were added 1-phenylpiperidine (**1a**, 32 mg, 0.2 mmol), acetone (0.5 mL), H_2O (0.5 mL), $T^+BF_4^-$ (97 mg, 0.4 mmol), and *tert*-butyl nitrite (98%, 36 μ L, 0.3 mmol). It was then stirred at room temperature for 30 min. Subsequent HRMS analysis of the resulting mixture showed that intermediate 1-phenyl-5-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-2,3,4,5-tetrahydropyridin-1-ium tetrafluoroborate (**D**) (calcd, 425.2358; found, 425.2355) was formed.

6.5. To a reaction tube equipped with a stir bar were added 1-phenylpiperidine (**1a**, 32 mg, 0.2 mmol), acetone (1 mL), $T^+BF_4^-$ (97 mg, 0.4 mmol), *tert*-butyl nitrite (98%, 36 μ L, 0.3 mmol), and 4 Å molecular sieves (100 mg, activated at 500 °C for 5 h before use). The resulting mixture was then stirred at room temperature under air for 1 h. Subsequent TLC analysis of the resulting mixture showed that there was no desired product **3a** formed from this reaction.

6.6. To a reaction tube equipped with a stir bar were added 1-phenylpiperidine (**1a**, 32 mg, 0.2 mmol), acetone (0.5 mL), $H_2^{18}O$ (0.5 mL), $T^+BF_4^-$ (97 mg, 0.4 mmol), and *tert*-butyl nitrite (98%, 36 μ L, 0.3 mmol). The resulting mixture was then stirred at room temperature under air for 1 h. Upon completion, subsequent HRMS analysis of the reaction mixture showed that $[^{18}O_1]$ -**3a**, $[^{18}O_2]$ -**3a** and $[^{16}O]$ -**3a** were formed in a ratio of 13.7:6.3:1 (Fig. S1).












	RT [min]	Area	Int. Type	I	S/N	Chromatogram	FWHM [min]
1	2.7	13125424.0	Chromatogram	359055	77.6	EIC 364.0000 +All MS	0.3
2	2.7	6049227.0	Chromatogram	183933	114.2	EIC 366.0000 +All MS	0.3
3	2.7	956292.9	Chromatogram	94498	24.3	EIC 362.0000 +All MS	0.2




Fig. S1 Copy of HRMS Spectra of the Reaction Mixture


III. Copies of the NMR spectra of 2a-2p, 2', 2'', I, II, and III






























































































































































































































IV. Copies of the NMR spectra of 3a-3t











































































9.942 9.931 7.588 7.584 7.582 7.578 7.441 7.436 7.427 7.424 7.421 7.416 7.409 7.389 7.356 7.348 7.343 7.336 7.332 7.328 7.326 7.321 7.274 4.216 4.206 4.197 4.190 4.181 4.171 4.015 4.002 3.993 3.981 3.969 2.085 2.081 2.076 2.067 2.064 2.054 2.050 2.046 1.827 1.821 1.812 1.807 1.801 1.542 1.516 1.483 1.457 1.447 1.443 1.417 1.409 1.396 1.383 1.374 1.371 1.362 1.359 1.349 1.349 1.337 1.079 1.062







205.091 142.397 135.477 130.617 127.236 119.313 117.045 90.480 77.421 77.312 77.103 76.785 61.018 60.064 41.581 40.245 40.166 34.265 34.120 34.026 28.689 20.527 20.440 17.031 15.514

































V. Copies of the NMR spectra of 4a-4d











4b






4b











4d





4d





VI. Copies of the NMR spectra of 5a-5d










5b





5b












5c





5c








5d



5d



VII. X-ray Crystal Structures and Data of **2m**




Fig. S2 X-ray structure of **2m**

X-ray structure determination. Single crystals suitable for X-ray diffraction was obtained by slow evaporation of the solvent from a Et₂O/hexane solution of **2m**. Crystal data collection and refinement parameters of **2m** are summarized in Table S1. Intensity data were collected at 296.83 K on a SuperNova Dual diffractometer using mirror-monochromated Cu K α radiation, $\lambda = 1.54184 \text{ \AA}$. The data were corrected for decay, Lorentz, and polarization effects as well as absorption and beam corrections based on the multi-scan technique. The structure was solved by a combination of direct methods in SHELXTL and the difference Fourier technique, and refined by full-matrix least-squares procedures. Non hydrogen atoms were refined with anisotropic displacement parameters. The H-atoms were either located or calculated and subsequently treated with a riding model.

Table S1 Crystallographic data and structure refinement results of **2m**


Empirical formula	C ₁₂ H ₁₃ FN ₂ O ₂
Formula weight	236.24
Temp, K	296.83(10)
Crystal system	monoclinic
Space group	P2 ₁ /c

$a, \text{Å}$	10.3361(8)
$b, \text{Å}$	15.5990(14)
$c, \text{Å}$	7.4565(5)
$\alpha (^\circ)$	90
$\beta (^\circ)$	105.716(8)
$\gamma (^\circ)$	90
Volume, Å^3	1157.29(16)
Z	4
$d_{\text{calc}}, \text{g cm}^{-3}$	1.356
$\lambda, \text{Å}$	1.54184
μ, mm^{-1}	0.878
No. of data collected	5095
No. of unique data	2223/0/155
R_{int}	0.0144
Goodness-of-fit on F^2	1.074
$R_1, wR_2 (I > 2\sigma(I))$	0.0493, 0.1291
R_1, wR_2 (all data)	0.0649, 0.1557


VIII. Copies of the DEPT 135, DEPT 90, C-H HSQC, H-H COSY Spectra of 3a

According to the DEPT 135 and DEPT 90 spectra of **3a** and the cross-peaks of **3a**-H4 to **3a**-C4 and **3a**-H1 to **3a**-C1 appeared on the C-H HSQC spectrum of **3a**, we could deduce that the peaks at 87.6 ppm and 43.4 ppm should be **3a**-C4 and **3a**-C1, respectively, and the peak of **3a**-H4 should on the left of the peak of **3a**-H1. In addition, the cross-peaks of **3a**-H5 to **3a**-H4 appeared on the H-H COSY spectrum of **3a** indicating that **3a**-H5 is adjacent to **3a**-H4.


Copies of the DEPT 135 and DEPT 90 Spectra of 3a



Copy of the C-H HSQC Spectrum of 3a




Copy of the H-H COSY Spectrum of 3a




IX. (1) Copies of DEPT 135, DEPT 90, C-H HSQC, H-H COSY, C-H HMBC, TOCSY spectra of 4d

According to the DEPT 135 and DEPT 90 spectra of **4d**, the cross-peaks of **4d**-H3 to **4d**-C3, **4d**-H4 to **4d**-C4, **4d**-H5 to **4d**-C5, **4d**-H6 to **4d**-C6, and **4d**-H7 to **4d**-C7 appeared on the C-H HSQC spectrum of **4d**, and the cross-peaks of **4d**-H3 to **4d**-H4, **4d**-H4 to **4d**-H5, **4d**-H7 to **4d**-H6, and **4d**-H6 to **4d**-H5 appeared on the H-H COSY spectrum of **4d**, we could deduce that the peaks at 152.7 ppm, 81.7 ppm, 53.6 ppm, 27.6 ppm and 25.5 ppm should be **4d**-C3, **4d**-C4, **4d**-C7, **4d**-C5, and **4d**-C6, respectively. Moreover, it also suggests that **4d**-H3 and **4d**-H5 should be adjacent to **4d**-H4, **4d**-H5 should be adjacent to **4d**-H6, and **4d**-H6 should be adjacent to **4d**-H7. The cross-peaks of **4d**-C3 to **4d**-H4, **4d**-H5 and **4d**-H6, **4d**-C4 to **4d**-H3, **4d**-H5 and **4d**-H6, **4d**-C7 to **4d**-H5 and **4d**-H6, **4d**-C5 to **4d**-H3, **4d**-H4, **4d**-H7 and **4d**-H6, and **4d**-C6 to **4d**-H4, **4d**-H5 and **4d**-H7 appeared on the C-H HMBC spectrum of **4d** could further verify the above deduction. In addition, the protons of **4d**-H3, **4d**-H4, **4d**-H5, **4d**-H6, and **4d**-H7 within the same spin system can be detected in the H-H TOCSY spectrum of **4d**.


Copy of the DEPT 135 Spectrum of 4d




Copy of the DEPT 90 Spectrum of 4d




Copy of the C-H HSQC Spectrum of 4d




Copy of the H-H COSY Spectrum of 4d



Copy of the C-H HMBC Spectrum of 4d




Copy of the TOCSY Spectrum of 4d




(2) Copies of DEPT 135, DEPT 90, C-H HSQC, H-H COSY, C-H HMBC, TOCSY spectra of 5c

According to the DEPT 135 and DEPT 90 spectra of **5c** the cross-peaks of **5c-H3** to **5c-C3**, **5c-H4** to **5c-C4**, **5c-H5** to **5c-C5**, **5c-H6** to **5c-C6**, and **5c-H7** to **5c-C7** appeared on the C-H HSQC spectrum of **5c**, and the cross-peaks of **5c-H3** to **5c-H4**, **5c-H4'** to **5c-H4**, **5c-H4** to **5c-H5**, **5c-H7** to **5c-H6**, and **5c-H6** to **5c-H5** appeared on the H-H COSY spectrum of **5c**, we could deduce that the peaks at 157.4 ppm, 70.2 ppm, 54.3 ppm, 31.4 ppm and 25.9 ppm should be **5c-C3**, **5c-C4**, **5c-C7**, **5c-C5** and **5c-C6**, respectively. Moreover, it also suggests that **5c-H3** and **5c-H5** should be adjacent to **5c-H4**, **5c-H4'** should be adjacent to **5c-H4**, **5c-H5** should be adjacent to **5c-H6**, and **5c-H6** should be adjacent to **5c-H7**. The cross-peaks of **5c-C3** to **5c-H4'**, **5c-H4**, and **5c-H5**, **5c-C4** to **5c-H3**, **5c-H4'**, **5c-H5** and **5c-H6**, **5c-C7** to **5c-H5** and **5c-H6**, **5c-C5** to **4d-H3**, **5c-H4'**, **4d-H4**, **4d-H7** and **4d-H6**, and **4d-C6** to **4d-H4**, **4d-H5**, and **4d-H7** appeared on the C-H HMBC spectrum of **5c** could further verify the above deduction. In addition, the protons of **5c-H3**, **5c-H4'**, **5c-H4**, **5c-H5**, **5c-H6**, and **5c-H7** within the same spin system can be detected in the H-H TOCSY spectrum of **5c**.


Copy of the DEPT 135 Spectrum of 5c




Copy of the DEPT 90 Spectrum of 5c




Copy of the C-H HSQC Spectrum of 5c




Copy of the H-H COSY Spectrum of 5c



Copy of the C-H HMBC Spectrum of 5c



Copy of the TOCSY Spectrum of 5c



X. References

- (1) H. Richter and Mancheño, O. G. *Eur. J. Org. Chem.*, 2010, 4460.
- (2) F. Wang, Y. He, M. Tian, X. Zhang and X. Fan, *Org. Lett.*, 2018, **20**, 864.
- (3) K. He, P. Li, S. Zhang, Q. Chen, H. Ji, Y. Yuan and X. Jia, *Chem. Commun.*, 2018, **54**, 13232.
- (4) Y. He, Z. Zheng, Y. Liu, J. Qiao, X. Zhang and X. Fan, *Org. Lett.*, 2019, **21**, 1676